Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition

Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases